Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
477.60 ^USD	+3.06%		-2.39%	-17.99%

Feb. 05	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule	RE
Feb. 02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE

Madrigal Pharmaceuticals, Inc. Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Published on 01/09/2026 at 09:22 am EST

S&P Capital IQ

MADRIGAL PHARMACEUTICALS, INC.

+3.06%

PFIZER INC.

+2.76%

Madrigal Pharmaceuticals, Inc. announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company's leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver. The company will present more details at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 1:30 p.m. PST.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MADRIGAL PHARMACEUTICALS, INC.	477.60USD	+3.06%	-2.39%	10.52B
	PFIZER INC.	27.22USD	+2.76%	+2.95%	151B

Latest news about Madrigal Pharmaceuticals, Inc.

Feb. 05	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule	RE
Feb. 02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
Jan. 28	Barclays Initiates Coverage on Madrigal Pharmaceuticals With Overweight Rating, $964 Price Target	MT
Jan. 26	Madrigal Pharmaceuticals Insider Sold Shares Worth $449,339, According to a Recent SEC Filing	MT
Jan. 22	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4)	RE
Jan. 21	Madrigal Pharmaceuticals announces grant of inducement award under Nasdaq Listing Rule 5635(c)(4)	RE
Jan. 20	Madrigal Pharmaceuticals Insider Sold Shares Worth $344,173, According to a Recent SEC Filing	MT
Jan. 20	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,098,343, According to a Recent SEC Filing	MT
Jan. 13	Madrigal Pharmaceuticals Insider Sold Shares Worth $9,617,312, According to a Recent SEC Filing	MT
Jan. 12	Madrigal Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
Jan. 09	Madrigal Pharmaceuticals, Inc. Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor	CI
Jan. 09	Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat	RE
Jan. 09	Madrigal Pharmaceuticals Granted Worldwide Exclusivity for Pfizer Liver Disease Drug	MT
Dec. 19	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
Dec. 11	Madrigal Pharmaceuticals, Inc. Appoints Rita Thakkar as Senior Vice President and Chief Accounting Officer, Effective January 12, 2026	CI
Dec. 11	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
Dec. 04	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing	MT
Dec. 04	Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash	CI
Dec. 04	Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals	RE
Dec. 03	Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing	MT
Nov. 21	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,082,986, According to a Recent SEC Filing	MT
Nov. 20	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4)	RE
Nov. 20	Madrigal Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08:30 AM
Nov. 20	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
Nov. 19	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT

Chart Madrigal Pharmaceuticals, Inc.

Duration

Period

MDGL: Dynamic Chart

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâ€™s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Employees

528

Sector

Biotechnology & Medical Research

Calendar

Feb. 19 - Q4 2025 Earnings Release

More about the company